<DOC>
	<DOCNO>NCT02651584</DOCNO>
	<brief_summary>Phase III , randomize , double-blind , double-dummy , active-controlled , parallel group multi-center trial , design evaluate non-inferiority CAM2038 compare exist standard care ( SL BPN ) initiation maintenance treatment BPN .</brief_summary>
	<brief_title>Clinical Trial CAM2038 , Long-acting Subcutaneous Buprenorphine Injections Treatment Patients With Opioid Dependence</brief_title>
	<detailed_description>This Phase III , randomize , double-blind , double-dummy , active-controlled , parallel group multi-center trial , design evaluate non-inferiority CAM2038 compare exist standard care ( SL BPN ) initiation maintenance treatment BPN . The trial involve 4 phase : Screening , Phase 1 ( weekly visit ) , Phase 2 ( monthly visit ) , Follow-up . Approximately 380 subject ( 190 subject per arm ) randomize .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Subject must provide write informed consent prior conduct trialrelated procedure . 2 . Male female , 1865 year age , inclusive . 3 . Diagnosis moderate severe opioid use disorder ( DSMV ) . 4 . Voluntarily seek treatment opioid use disorder . 5 . Have receive medicationassisted treatment opioid use disorder within 60 day prior randomization . 6 . Considered Investigator good candidate BPN treatment , base medical psychosocial history . 7 . Female subject childbearing potential must willing use reliable method contraception entire trial ( Screening visit Followup visit ) 1 . Current diagnosis Acquired Immune Deficiency Syndrome ( AIDS ) . 2 . Current diagnosis chronic pain require opioids treatment . 3 . Current DSMV diagnosis moderate severe substance use disorder psychoactive substance opioids , caffeine nicotine ( e.g. , alcohol , cocaine , sedative ) . 4 . Pregnant lactate plan become pregnant trial . 5 . Hypersensitivity allergy BPN opioids , naloxone opioid antagonist , excipients CAM2038 SL BPN . 6 . Requires current use agent strong inhibitor inducer cytochrome P450 3A4 ( CYP3A4 ) azole antifungal ( e.g. , ketoconazole ) , macrolide antibiotic ( e.g. , clarithromycin ) , protease inhibitor ( e.g. , ritonavir , indinavir , saquinavir ) . 7 . Active hepatitis . Subjects significant viral load , acute sign inflammation , clinical necessity therapy allow , discretion Investigator . 8 . Recent history current evidence suicidal ideation active suicidal behavior base Columbia Suicide Severity Rating Scale ( CSSRS ) ( `` Yes '' response question 4 5 ) . 9 . Any pending legal action could prohibit participation compliance trial . 10 . Exposure investigational drug within 4 week prior Screening . 11 . Participants history risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) electrocardiogram ( ECG ) demonstrate Fridericia 's correct QT interval ( QTcF ) &gt; 450 msec male QTcF &gt; 470 female screen . 12 . Aspartate aminotransferase ( AST ) level &gt; 3 X upper limit normal , alanine aminotransferase ( ALT ) level &gt; 3 X upper limit normal , total bilirubin &gt; 1.5 X upper limit normal , creatinine &gt; 1.5 X upper limit normal Screening laboratory assessment , clinically significant laboratory abnormality , opinion Investigator may prevent subject safely participate trial . 13 . Significant symptom , medical condition , circumstance , opinion Investigator , would preclude compliance protocol , adequate cooperation trial obtain informed consent , may prevent subject safely participate trial ( include , limited , risk describe precaution , warning , contraindication current version Investigator 's Brochure CAM2038 ) . 14 . Is employee Investigator trial site , direct involvement propose trial trial direction Investigator trial site , family member employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>